VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
Hong Kong Exchanges and Clearing Limited vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Hong Kong Exchanges and Clearing Limited
0388.HK · Hong Kong Stock Exchange (HKEX)
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Hong Kong Exchanges and Clearing Limited's moat claims, evidence, and risks.
View 0388.HK analysisVertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 92 / 100 for Hong Kong Exchanges and Clearing Limited).
- Segment focus: Hong Kong Exchanges and Clearing Limited has 4 segments (52.6% in Cash Markets); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Monopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Hong Kong Exchanges and Clearing Limited has 9 moat types across 5 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.
Primary market context
Hong Kong Exchanges and Clearing Limited
Cash Markets
Exchange-based cash equities trading, clearing and settlement in Hong Kong (including Stock Connect cash markets)
Hong Kong (with Mainland China Connect linkage)
Brokers, banks, proprietary trading firms, and investors; listed issuers via primary/secondary markets
Exchange operator + clearing/settlement/depository operator
52.6%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
99.9%
Side-by-side metrics
Moat coverage
Shared moat types
Hong Kong Exchanges and Clearing Limited strengths
Vertex Pharmaceuticals Incorporated strengths
Segment mix
Hong Kong Exchanges and Clearing Limited segments
Full profile >Cash Markets
Monopoly
Equity and Financial Derivatives
Monopoly
Commodities (LME and related)
Oligopoly
Data and Connectivity
Quasi-Monopoly
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.